Bayesian Sequential Learning for Clinical Trials of Multiple Correlated Medical Interventions

Stephen E. Chick (), Noah Gans () and Özge Yapar ()
Additional contact information
Stephen E. Chick: Technology & Operations Management Area, INSEAD, 77305 Fontainebleau, France
Noah Gans: Operations, Information and Decisions Department, The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania 19104
Özge Yapar: Operations & Decision Technologies Department, Kelley School of Business, Indiana University, Bloomington, Indiana 47405

Management Science, 2022, vol. 68, issue 7, 4919-4938

Abstract: We propose and analyze the first model for clinical trial design that integrates each of three important trends intending to improve the effectiveness of clinical trials that inform health-technology adoption decisions: adaptive design, which dynamically adjusts the sample size and allocation of interventions to different patients; multiarm trial design, which compares multiple interventions simultaneously; and value-based design, which focuses on cost-benefit improvements of health interventions over a current standard of care. Example applications are to seamless phase II/III dose-finding trials and to trials that test multiple combinations of therapies. Our objective is to maximize the expected population health-economic benefit of health-technology adoption decisions less clinical trial costs. We show that unifying the adaptive, multiarm, and value-based approaches to trial design can reduce the cost and duration of multiarm trials with efficient adaptive look ahead policies that focus on value to patients and account for correlated rewards across arms. Features that differentiate our approach from much other work on stochastic optimization include stopping times that balance sampling costs and the expected value of information of those samples, performance guarantees offered by new asymptotic convergence proofs, and the modeling of arms’ potentially different sampling costs. Our proposed solution can be computed feasibly and can randomize patients. The class of trials for the base model assumes that health-economic data are collected and observed quickly. Related work from Bayesian optimization can enable the further inclusion of trials with intermediate duration delays between the time of treatment initiation and observation of outcomes.

Keywords: Bayesian; clinical trials; health economics; sequential experimentation; ranking and selection; simulation optimization; dynamic programming (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://dx.doi.org/10.1287/mnsc.2021.4137 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:inm:ormnsc:v:68:y:2022:i:7:p:4919-4938

Access Statistics for this article

More articles in Management Science from INFORMS Contact information at EDIRC.
Bibliographic data for series maintained by Chris Asher ().